Blood
Articles in this Issue
Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)
Abstract Introduction: DDX41-mutated AML comprises 2–5% of new AML cases, often seen in males, and is frequently associated with germline mu...
Dual antithrombotic therapy in venous thromboembolism: A propensity-matched analysis of safety and efficacy by anticoagulant type. insights from the riete registry.
Abstract Introduction: Venous thromboembolism (VTE) is the third leading cause of acute cardiovascular events and is associated with signifi...
Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors
Abstract Introduction: The menin-KMT2A complex plays a major role in activating the HOXA-MEIS1 pathway. Abnormalities in this pathway lead to...
A retrospective study to assess real-world treatment patterns and outcomes in luspatercept-treated patients with myelofibrosis-associated anemia who required red blood cell transfusion in the United States
Abstract Introduction Most patients with myelofibrosis (MF) will develop anemia, contributing to poor quality of life an...
Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone
Abstract Purpose: Warm autoimmune hemolytic anemia (wAIHA) is defined as the enhanced destruction of erythrocytes through autoimmune process...
Moyamoya syndrome in sickle cell disease
Abstract Introduction: Sickle cell crisis is a common cause of admission for patients with sickle cell disease (SCD) but...
Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia
Abstract Introduction R/R AML carries significant therapeutic challenges and has a 5-year OS below 10%. The integration of multiomics profili...
High-intensity purine analogue-based therapy for refractory/relapsed Acute Myeloid Leukemia (RR-AML): A single-institution experience
Abstract Background: Refractory/relapsed acute myeloid leukemia (RR-AML) remains a significant therapeutic challenge, wi...
Utility of peripheral blood cell-free DNA in detecting minimal residual disease in patients receiving CAR T-cell therapy for B-acute lymphoblastic leukemia (B-ALL)
Abstract Introduction: Current modalities for minimal residual disease (MRD) detection in B-ALL include flow cytometry and next-generation s...
Multiple myeloma treatment patterns in China: Analysis of the CancerMPact treatment architecture database
Abstract Background The most common treatment classes used for the management of multiple myeloma (MM) include proteasome inhibitors (PIs),...
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Abstract Durable responses to currently available CAR T cell therapies for relapsed or refractory multiple myeloma (R/R MM) are limited in p...
Epigenetic reactivation of a tumor suppressor program in AML.
Abstract Inactivation of tumor suppressor genes (TSGs) impart a cellular fitness in cancers, including acute myeloid leukemia (AML). The sil...
Real-world comparative outcomes of CAR-T cell therapy versus bispecific T-cell engagers in patients with relapsed acute lymphoblastic leukemia
Abstract Introduction: The emergence of novel immunotherapies and cellular therapies has transformed the treatment landscape for hematologic...
Disparities in survival outcomes among adolescent and young adults vs adult populations with Hodgkin lymphoma: A population based SEER study
Abstract Introduction Hodgkin lymphoma (HL) outcomes have improved markedly over recent decades, yet population-based data on overall surviv...
Easix, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura
Abstract Background Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy caused...
Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis
Abstract Background Relapsed/refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL) remains challenging to treat, and durable remission is ofte...
Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia
Abstract Introduction. Hypomethylating agent (HMA) plus venetoclax (VEN) regimen, until disease progression or unacceptable toxicity, is the...
Distinct transcriptomic signatures in non-hispanic black AML patients with NPM1 mutations reveal potential drivers of poor prognosis
Abstract Introduction: Non-Hispanic Black (NHB) patients with Acute Myeloid Leukemia (AML) harboring NPM1 mutations (NPM1c), despite being c...
Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling
Abstract Background: HIV infection increases lymphoma risk, with many cases linked to co-infection with latent Epstein-Barr Virus (EBV). Imm...
Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)
Abstract Background: Obe-cel is a CD19-directed autologous CAR T therapy with a fast off-rate binding domain and a 4-1BB-ζ co-stimulatory do...
Automated grading of castleman disease histopathology using an attention-based multiple-instance learning model
Abstract Castleman Disease (CD) is a heterogeneous group of rare lymphoproliferative disorders. The diagnosis requires histopathologic inter...
Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML
Abstract Background: Hypomethylating agents (HMAs) with and without venetoclax (Ven) have improved outcomes in elderly and less fit patients...
Ferroptosis escape in AML stem cells uncovered by single-cell profiling and reversed by STAT3/NRF2 inhibition
Abstract Chemo resistant Leukemic stem cells (LSCs) with leukemia re-initiating potential are a key contributor to relapse refractory diseas...
Clinically significant cytomegalovirus infection (csCMVi) after matched related donor allogeneic HSCT using post-transplant cyclophosphamide: A systematic review and meta-analysis.
Abstract Background: Post-transplant cyclophosphamide (PTCy) is increasingly used as graft-versus-host disease (GVHD) prophylaxis in matched...
Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia
Abstract Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for patie...